{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:38:40Z","timestamp":1778323120344,"version":"3.51.4"},"reference-count":69,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY025214"],"award-info":[{"award-number":["EY025214"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The pandemic associated with Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV2) and its disease named COVID-19 challenged the scientific community to discover effective therapeutic solutions in a short period. Repurposing existing drugs is one viable approach that emphasizes speed during these urgent times. Famotidine, a class A G protein-coupled receptor antagonist used for the treatment of gastroesophageal reflux was recently identified in an in silico screening. Additionally, a recent retrospective clinical report showed that the treatment with famotidine provided a good outcome in patients infected with SARS-CoV2. A clinical trial testing effectiveness of famotidine in combination with hydroxychloroquine is currently ongoing in the United States (US). In the 1990s, famotidine was described as an antiviral agent against human immunodeficiency virus (HIV). Interestingly, some HIV protease inhibitors are presently being used against SARS-CoV2. However, it is not clear if famotidine could be effective against SARS-CoV2. Thus, by using a computational analysis, we aimed to examine if the antiviral effect of famotidine could be related to the inhibition of proteases involved in the virus replication. Our results showed that famotidine could interact within the catalytic site of the three proteases associated with SARS-CoV2 replication. However, weak binding affinity of famotidine to these proteases suggests that a successful famotidine therapy could likely be achieved only in combination with other antiviral drugs. Finally, analysis of famotidine\u2019s pharmacokinetic parameters indicated that its effect against SARS-CoV2 infection could be reached only upon intravenous administration. This work will contribute to the pharmacological knowledge of famotidine as an antiviral agent against SARS-CoV2.<\/jats:p>","DOI":"10.3390\/biom10060954","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T12:41:36Z","timestamp":1593002496000},"page":"954","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative against SARS-CoV2: An In Silico Analysis"],"prefix":"10.3390","volume":"10","author":[{"given":"Joseph T.","family":"Ortega","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Cleveland Center for Membrane and Structural Biology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa","family":"Serrano","sequence":"additional","affiliation":[{"name":"Unidad de Qu\u00edmica Medicinal, Facultad de Farmacia, Universidad Central de Venezuela, Caracas 1041-A, Venezuela"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-8685","authenticated-orcid":false,"given":"Beata","family":"Jastrzebska","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Cleveland Center for Membrane and Structural Biology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Graham, R.L., and Baric, R.S. (2020). SARS-CoV-2: Combating Coronavirus Emergence. Immunity.","DOI":"10.1016\/j.immuni.2020.04.016"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12098-020-03263-6","article-title":"A Review of Coronavirus Disease-2019 (COVID-19)","volume":"87","author":"Singhal","year":"2020","journal-title":"Indian J. Pediatr."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tu, Y.F., Chien, C.S., Yarmishyn, A.A., Lin, Y.Y., Luo, Y.H., Lin, Y.T., Lai, W.Y., Yang, D.M., Chou, S.J., and Yang, Y.P. (2020). A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072657"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.15190\/d.2020.5","article-title":"COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus","volume":"8","author":"Jan","year":"2020","journal-title":"Discoveries (Craiova)"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1042\/BCJ20200223","article-title":"Expanding our understanding of the role polyprotein conformation plays in the coronavirus life cycle","volume":"477","author":"Gildenhuys","year":"2020","journal-title":"Biochem. J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ghosh, A.K., Brindisi, M., Shahabi, D., Chapman, M.E., and Mesecar, A.D. (2020). Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics. ChemMedChem.","DOI":"10.1002\/cmdc.202000223"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gordon, D.E., Jang, G.M., Bouhaddou, M., Xu, J., Obernier, K., White, K.M., O\u2019Meara, M.J., Rezelj, V.V., Guo, J.Z., and Swaney, D.L. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature.","DOI":"10.1038\/s41586-020-2286-9"},{"key":"ref_9","first-page":"4576","article-title":"The viral, epidemiologic, clinical characteristics and potential therapy options for COVID-19: A review","volume":"24","author":"Li","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_10","first-page":"4597","article-title":"An update on the status of COVID-19: A comprehensive review","volume":"24","author":"Zhao","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.12688\/f1000research.22457.2","article-title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates","volume":"9","author":"Chen","year":"2020","journal-title":"F1000Res"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"He, J., Tao, H., Yan, Y., Huang, S.Y., and Xiao, Y. (2020). Molecular Mechanism of Evolution and Human Infection with SARS-CoV-2. Viruses, 12.","DOI":"10.3390\/v12040428"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41392-020-0178-y","article-title":"Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro)","volume":"5","author":"Mengist","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_14","first-page":"400","article-title":"Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target","volume":"19","author":"Ortega","year":"2020","journal-title":"EXCLI J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jcv.2005.03.005","article-title":"Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenza","volume":"34","author":"Savarino","year":"2005","journal-title":"J. Clin. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"ofaa105","DOI":"10.1093\/ofid\/ofaa105","article-title":"Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_19","first-page":"4539","article-title":"Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19","volume":"24","author":"Meo","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5056\/jnm.2014.20.1.6","article-title":"New and future drug development for gastroesophageal reflux disease","volume":"20","author":"Fass","year":"2014","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/bioinformatics\/bti770","article-title":"The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling","volume":"22","author":"Arnold","year":"2006","journal-title":"Bioinformatics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"ref_23","first-page":"1037","article-title":"Antiviral activity of flavonoids present in aerial parts of Marcetia taxifolia against Hepatitis B virus, Poliovirus, and Herpes Simplex Virus in vitro","volume":"18","author":"Ortega","year":"2019","journal-title":"EXCLI J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"W407","DOI":"10.1093\/nar\/gkm290","article-title":"ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins","volume":"35","author":"Wiederstein","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"Procheck\u2014A Program to Check the Stereochemical Quality of Protein Structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J. Appl. Crystallogr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/B:JCAM.0000035186.90683.f2","article-title":"VEGA--an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming","volume":"18","author":"Pedretti","year":"2004","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ortega, J.T., and Jastrzebska, B. (2019). The Retinoid and Non-Retinoid Ligands of the Rod Visual G Protein-Coupled Receptor. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246218"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1186\/1471-2105-13-S14-S13","article-title":"High-Throughput parallel blind Virtual Screening using BINDSURF","volume":"13","author":"Cecilia","year":"2012","journal-title":"BMC Bioinform."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds","volume":"115","author":"Mesecar","year":"2015","journal-title":"Antiviral. Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Freedberg, D.E., Conigliaro, J., Sobieszczyk, M.E., Markowitz, D.D., Gupta, A., O\u2019Donnell, M.R., Li, J., Tuveson, D.A., Jin, Z., and Turner, W.C. (2020). Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. medRxiv.","DOI":"10.1053\/j.gastro.2020.05.053"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., and Li, X. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B.","DOI":"10.1016\/j.apsb.2020.02.008"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dai, W., Zhang, B., Su, H., Li, J., Zhao, Y., Xie, X., Jin, Z., Liu, F., Li, C., and Li, Y. (2020). Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science.","DOI":"10.1126\/science.abb4489"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10096-005-0004-z","article-title":"Treatment of severe acute respiratory syndrome","volume":"24","author":"Lai","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.3346\/jkms.2020.35.e79","article-title":"Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: The Application of Lopinavir\/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Khan, S.A., Zia, K., Ashraf, S., Uddin, R., and Ul-Haq, Z. (2020). Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J. Biomol. Struct. Dyn., 1\u201310.","DOI":"10.1080\/07391102.2020.1751298"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Rut, W.Z., Zmudzinski, M., Lyu, Z., Nayak, D., Snipas, S.J., Bekes, M., Huang, T.T., Olsen, S.K., and Drag, M. (2020). Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design. bioRxiv.","DOI":"10.1101\/2020.04.29.068890"},{"key":"ref_39","unstructured":"Rimanshee, A., Amit, D., Vishal, P., and Mukesk, K. (2020). Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs. ChemRxiv Preprint."},{"key":"ref_40","first-page":"410","article-title":"Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis","volume":"19","author":"Ortega","year":"2020","journal-title":"EXCLI J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response","volume":"14","author":"Astuti","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104859","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","volume":"157","author":"McKee","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0024-3205(96)00553-X","article-title":"The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: Identification of a new class of antiviral agents","volume":"59","author":"Bourinbaiar","year":"1996","journal-title":"Life Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/aid.1997.13.281","article-title":"Effect of the oral anti-ulcer agent, cimetidine, on HIV type 1 replication","volume":"13","author":"Bourinbaiar","year":"1997","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrmicro2747","article-title":"The structural biology of HIV-1: Mechanistic and therapeutic insights","volume":"10","author":"Engelman","year":"2012","journal-title":"Nat. Rev. Microbiol"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"a007161","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/prot.22271","article-title":"Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin","volume":"75","author":"Sayer","year":"2009","journal-title":"Proteins"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1021\/ci034243x","article-title":"ESOL: Estimating aqueous solubility directly from molecular structure","volume":"44","author":"Delaney","year":"2004","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/ci200387c","article-title":"Revisiting the general solubility equation: In silico prediction of aqueous solubility incorporating the effect of topographical polar surface area","volume":"52","author":"Ali","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/jps.23614","article-title":"Plasma protein binding: From discovery to development","volume":"102","author":"Bohnert","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/138620710790596745","article-title":"Plasma protein binding in drug discovery and development","volume":"13","author":"Howard","year":"2010","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1128\/AAC.47.1.350-359.2003","article-title":"Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients","volume":"47","author":"Hsu","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Dhama, K., Sharun, K., Tiwari, R., Dadar, M., Malik, Y.S., Singh, K.P., and Chaicumpa, W. (2020). COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum. Vaccin. Immunother., 1\u20137.","DOI":"10.1080\/21645515.2020.1735227"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Yan, Y., Shin, W.I., Pang, Y.X., Meng, Y., Lai, J., You, C., Zhao, H., Lester, E., Wu, T., and Pang, C.H. (2020). The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17072323"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Li, H., Liu, S.M., Yu, X.H., Tang, S.L., and Tang, C.K. (2020). Coronavirus disease 2019 (COVID-19): Current status and future perspectives. Int. J. Antimicrob. Agents, 105951.","DOI":"10.1016\/j.ijantimicag.2020.105951"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Mirza, M.U., and Froeyen, M. (2020). Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. J. Pharm. Anal.","DOI":"10.20944\/preprints202003.0085.v1"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ton, A.T., Gentile, F., Hsing, M., Ban, F., and Cherkasov, A. (2020). Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds. Mol. Inform.","DOI":"10.26434\/chemrxiv.11860077"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/ijp.IJP_115_20","article-title":"Drug targets for corona virus: A systematic review","volume":"52","author":"Prajapat","year":"2020","journal-title":"Indian J. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jmv.25707","article-title":"Potential interventions for novel coronavirus in China: A systematic review","volume":"92","author":"Zhang","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_63","first-page":"218","article-title":"Mechanism of action of ribavirin in the treatment of chronic hepatitis C","volume":"3","author":"Te","year":"2007","journal-title":"Gastroenterol. Hepatol. (NY)"},{"key":"ref_64","first-page":"93","article-title":"[Present and future of therapy against hepatitis C]","volume":"57","author":"Jaspe","year":"2016","journal-title":"Investig. Clin."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: Efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e00293","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., and Vieira, V.E. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 105949.","DOI":"10.1101\/2020.03.16.20037135"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/6\/954\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:42:36Z","timestamp":1760175756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/6\/954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":69,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["biom10060954"],"URL":"https:\/\/doi.org\/10.3390\/biom10060954","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]}}}